Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide

Yosuke Okamura, Toshinori Fujie, Hitomi Maruyama, Makoto Handa, Yasuo Ikeda, Shinji Takeoka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

Original languageEnglish
Pages (from-to)1254-1262
Number of pages9
JournalTransfusion
Volume47
Issue number7
DOIs
Publication statusPublished - 2007 Jul
Externally publishedYes

Fingerprint

Hemostatics
Fibrinogen
Albumins
Bleeding Time
Tail
Hemorrhage
Platelet Transfusion
Blood Circulation
Blood Platelets
Injections
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide. / Okamura, Yosuke; Fujie, Toshinori; Maruyama, Hitomi; Handa, Makoto; Ikeda, Yasuo; Takeoka, Shinji.

In: Transfusion, Vol. 47, No. 7, 07.2007, p. 1254-1262.

Research output: Contribution to journalArticle

Okamura, Yosuke ; Fujie, Toshinori ; Maruyama, Hitomi ; Handa, Makoto ; Ikeda, Yasuo ; Takeoka, Shinji. / Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide. In: Transfusion. 2007 ; Vol. 47, No. 7. pp. 1254-1262.
@article{d7ea8fc2d2f24f288007b0db39f080b4,
title = "Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide",
abstract = "BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.",
author = "Yosuke Okamura and Toshinori Fujie and Hitomi Maruyama and Makoto Handa and Yasuo Ikeda and Shinji Takeoka",
year = "2007",
month = "7",
doi = "10.1111/j.1537-2995.2007.01265.x",
language = "English",
volume = "47",
pages = "1254--1262",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide

AU - Okamura, Yosuke

AU - Fujie, Toshinori

AU - Maruyama, Hitomi

AU - Handa, Makoto

AU - Ikeda, Yasuo

AU - Takeoka, Shinji

PY - 2007/7

Y1 - 2007/7

N2 - BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

AB - BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

UR - http://www.scopus.com/inward/record.url?scp=34250688226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250688226&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2007.01265.x

DO - 10.1111/j.1537-2995.2007.01265.x

M3 - Article

C2 - 17581161

AN - SCOPUS:34250688226

VL - 47

SP - 1254

EP - 1262

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 7

ER -